ERRATUM

Erratum to: *nab*-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

Mustapha Tehfe · Scot Dowden · Hagen Kennecke · Robert El-Maraghi ·
Bernard Lesperance · Felix Couture · Richard Letourneau · Helen Liu ·
Alfredo Romano

Published online: November 24, 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Erratum to: Adv Ther (2016) 33:747–759
DOI 10.1007/s12325-016-0327-4

The authors would like to correct the errors in Table 1 and text in the published article. The correct table and the text should read as below.

The online version of the original article can be found under doi:[10.1007/s12325-016-0327-4](https://doi.org/10.1007/s12325-016-0327-4).

M. Tehfe (✉) · R. Letourneau
Centre hospitalier de l'université de Montréal
(CHUM), Montreal, QC, Canada
e-mail: mustapha.tehfe.chum@ssss.gouv.qc.ca

S. Dowden
Tom Baker Cancer Centre, Calgary, AB, Canada

H. Kennecke
British Columbia Cancer Agency, Vancouver, BC,
Canada

R. El-Maraghi
Royal Victoria Regional Health Centre, Barrie, ON,
Canada

B. Lesperance
Hôpital du Sacré-Coeur de Montreal, Montreal, QC,
Canada

F. Couture
Centre hospitalier universitaire de Québec (CHUQ),
Hôtel-Dieu de Québec, CHUM, Montreal, QC,
Canada

H. Liu · A. Romano
Celgene Corporation, Summit, NJ, USA

In Table 1, the numbers for the intent-to-treat population for biliary stent and previous Whipple procedure were erroneously switched. Table 1 should appear as below.

The corresponding text for Table 1 under the Baseline Characteristics heading in the Results section should read, “Fewer patients in the Canadian cohort had a KPS of 100 than in the ITT population,” i.e., removing “or previous Whipple procedure” from the original sentence which read “Fewer patients in the Canadian cohort had a KPS of 100 or previous Whipple procedure than in the ITT population.”

Under the Statistical Analyses section, the second-to-last sentence reads “A nonstratified log-rank test was PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.” It should read “A stratified log-rank test was used to compare PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.”

In the Discussion (last paragraph beginning at the bottom of page 756), the sentence reads, “Health Canada has approved *nab*-P + Gem and FOLFIRINOX for the treatment of patients with

Table 1 Baseline characteristics

Variable	Patients in Canada		ITT population [9] (<i>N</i> = 861)
	<i>nab</i> -P + Gem (<i>n</i> = 33)	Gem (<i>n</i> = 30)	
Age, median (range), years	61.0 (34–77)	61.5 (49–72)	63.0 (27–88)
Sex, <i>n</i> (%)			
Female	12 (36)	9 (30)	359 (42)
Male	21 (64)	21 (70)	502 (58)
KPS, <i>n</i> (%)			
100	2 (6)	3 (10)	138 (16) ^a
90	18 (55)	14 (47)	378 (44) ^a
80	9 (27)	12 (40)	277 (32) ^a
70	4 (12)	1 (3)	63 (7) ^a
60	0	0	2 (<1) ^a
Number of metastatic sites, <i>n</i> (%)			
1	4 (12)	1 (3)	54 (6)
2	11 (33)	11 (37)	408 (47)
≥3	18 (55)	18 (60)	399 (46)
Sites of metastases, <i>n</i> (%)			
Liver	27 (82)	25 (83)	725 (84)
Lung	14 (42)	18 (60)	337 (39)
Peritoneum	2 (6)	1 (3)	29 (3)
Pancreatic tumor location, <i>n</i> (%)			
Head	18 (55)	9 (30)	371 (43)
Body	11 (33)	11 (37)	268 (31)
Tail	4 (12)	10 (33)	215 (25)
Unknown	0	0	7 (1)
CA 19-9, <i>n</i> (%)			
Normal	3 (9)	3 (10)	116 (15) ^b
>ULN and <59 × ULN	11 (33)	11 (37)	242 (32) ^b
≥59 × ULN	16 (48)	11 (37)	392 (52) ^b
Unknown	3 (9)	5 (17)	111 (13) ^c
Biliary stent, <i>n</i> (%)	11 (33)	8 (27)	148 (17)

Table 1 continued

Variable	Patients in Canada		ITT population [9] (<i>N</i> = 861)
	<i>nab</i> -P + Gem (<i>n</i> = 33)	Gem (<i>n</i> = 30)	
Previous Whipple procedure, <i>n</i> (%)	3 (9)	2 (7)	62 (7)

CA 19-9 carbohydrate antigen 19-9, *Gem* gemcitabine, *ITT* intent-to-treat, *KPS* Karnofsky performance status, *nab*-P nab-paclitaxel, *ULN* upper limit of normal

^a Total evaluable patients = 858

^b Total evaluable patients = 750

^c This value was not reported in Ref. [9]

MPC based on the phase III MPACT and PRODIGE trials (ClinicalTrials.gov identifier, NCT00112658), respectively, in which *nab*-P + Gem and FOLFIRINOX demonstrated superior efficacy vs. Gem alone [4, 9, 20].” It should read, “Based on the results of the phase III MPACT and PRODIGE trials (ClinicalTrials.gov identifier, NCT00112658), both the *nab*-P + Gem and FOLFIRINOX regimens are accessible in Canada; however, Health Canada only reviewed and approved *nab*-P + Gem for the first-line treatment of MPC [4, 7, 9, 20].”

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.